NCT02984683 - Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 23, 2017

Primary Completion Date

September 7, 2018

Study Completion Date

September 7, 2018

Conditions

Triple Negative Breast Cancer

Interventions

DRUG

SAR566658 (ACT14884)

Pharmaceutical form:Solution Route of administration: Intravenous

Trial Locations (13)

Investigational Site Number 0560001, Leuven

Investigational Site Number 2030002, Prague

Investigational Site Number 3800003, Genova

Investigational Site Number 3800001, Milan

Investigational Site Number 7240005, Lleida

Investigational Site Number 7240001, Madrid

Investigational Site Number 7240006, Madrid

Investigational Site Number 7240003, Seville

Investigational Site Number 7240004, Valencia

Investigational Site Number 3800004, Roma

Investigational Site Number 5280001, Maastricht

Investigational Site Number 5280002, Rotterdam

Investigational Site Number 7240002, Barcelona